The $180M sale is a significant positive catalyst for RCKTW given the tiny market cap (~$1M). Monitor HSR clearance and closing. If completed, expect a sharp re-rating as cash balances will vastly exceed current market cap.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 28 $0.0193entry
- T+1 · 7mo ago 0.00%α +0.01% · $0.0193
- T+5 · 7mo ago 0.00%α −1.69% · $0.0193
- T+20 · 6mo ago 0.00%α −5.46% · $0.0193
- T+60 · 4mo ago −86.01%α −90.00% · $0.002700
Price Chart
How similar events traded
Executive Summary
Rocket Pharmaceuticals announced the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million in cash, providing non-dilutive capital that extends the company's cash runway into the second quarter of 2028. This strengthens the balance sheet and supports advancement of its cardiovascular gene therapy pipeline.
Key Financial Metrics
Key Facts
- Sold Rare Pediatric Disease Priority Review Voucher for $180 million in cash
- Proceeds are non-dilutive and expected to extend cash runway into Q2 2028
- Transaction subject to HSR waiting period expiration or termination
- PRV was awarded from FDA accelerated approval of KRESLADI (marnetegragene autotemcel)
Financial Impact
$180 million cash inflow, extending cash runway into Q2 2028
Risk Factors
- Transaction may not close due to HSR or other conditions
- Proceeds do not guarantee success of pipeline programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-017275 |
| Document: ef20071574_ex99-1.htm | 0001140361-26-017275 |
| Document: 0001140361-26-017275-index-headers.html | 0001140361-26-017275 |
| Document: 0001140361-26-017275-index.html | 0001140361-26-017275 |
| Document: 0001140361-26-017275.txt | 0001140361-26-017275 |
Track record
4 reports on RCKTW
Filters
- May 13, 202626w ago 144 Neutral 2/10 Entry $0.0193 No price data
- May 7, 202627w ago 8-K Mixed 6/10 Entry $0.0193 to $0.001800 ▼ −90.67% −95.51% vs SPY
- May 7, 202627w ago 144 Neutral 3/10 Entry $0.0193 to $0.003200 ▼ −83.42% −87.25% vs SPY
- Apr 28, 202628w ago 8-K Bullish 8/10 Viewing Entry $0.0193 to $0.002700 ▼ −86.01% −90.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers